“Large Pericardial Effusions as a Manifestation of Graft Versus Host Disease: a Single Institution Retrospective Study”. M Norkin, V Ratanatharathorn, L Ayash, MH Abidi, LG Lum, Z Al-Kadhimi, ... Blood 114 (22), 4659, 2009 | | 2009 |
“NextGen” biologics: bispecific antibodies and emerging clinical results A Thakur, LG Lum Expert opinion on biological therapy 16 (5), 675-688, 2016 | 52 | 2016 |
101: Phase II Trial Evaluating Aprepitant (Ap) for Prevention of Nausea and Vomiting Secondary to High-Dose Cyclophosphamide (Cy) Administered to Patients Undergoing Autologous … MH Abidi, J Abrams, R Ibrahim, L Ayash, S Cronin, Z Al-Khadimi, L Lum, ... Biology of Blood and Marrow Transplantation 14 (2), 39-40, 2008 | | 2008 |
2011-204: Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies. BMS Protocol Number: CA-180-384 Principal Investigator A Deol, C Schiffer, V Ratanatharathorn, JP Uberti, LJ Ayash, D Bhutani, ... | | |
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
47 Universal outpatient immunotherapeutic approach for heme malignancies in the absence of donor chimerism: Anti-tumor responses in HLA-Haploidentical cell infusions in 100CGY … GA Colvin, J Lambert, LG Lum, R Rathore, MT Falvey, M Abedi, ... Biology of Blood and Marrow Transplantation 2 (9), 79, 2003 | | 2003 |
629-E Randomized trial comparing conventional vs novel treatment planning technique to improve the immune system during lung SBRT K Wijesooriya, JM Larner, PW Read, TN Showalter, LG Lum, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | | 2023 |
712 SPLENECTOMY AND PROPHYLACTIC ANTIBIOTICS IN THE MANAGEMENT OF THE WISKOTT-ALDRICH SYNDROME (WAS) LG Lum, DG Tubergen, RM Blaese Pediatric Research 12 (4), 482-482, 1978 | 4 | 1978 |
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L) 1 solid tumor patients without lymphodepleting … M Gutierrez, M Donato, R Reich-Slotky, S Patel, M Finlay, LG Lum, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
831 WISKOTT-ALDRICH SYNDROME: IMMUNE STATUS AFTER BONE MARROW TRANSPLANTATION LG Lum, HD Ochs, FL Johnson, RF Storb Pediatric Research 15 (4), 581-581, 1981 | | 1981 |
A CANINE MODEL FOR STUDYING IMMUNE RESPONSIVENESS W LADIGES, B JOHNSTON, L LUM, R STORB LABORATORY ANIMAL SCIENCE 36 (5), 553-553, 1986 | | 1986 |
A chemicogenetic interrogation of colorectal cancer identifies a shared chemical vulnerability in Wnt signaling and telomere length maintenance. O Kulak, B Holohan, X Wu, L Lum Cancer Research 73 (8_Supplement), 2115-2115, 2013 | | 2013 |
A HEXIM1-AIRE transcriptional counter-balance in trophoblasts regulates maternal-fetal mucosal immunity in pregnancy (MUC7P. 755) ZY Wang, G Sun, A Faucette, B Unger, P Hong, F Yao, J Guterman, ... The Journal of Immunology 192 (1_Supplement), 197.7-197.7, 2014 | | 2014 |
A Novel Combination of Anti-CD3 x Anti-CD123 Monoclonal Antibodies to Redirect Activated T Cells to Target Acute Myelogenous Leukemia E Kubicka, LG Lum, A Thakur Blood 130, 5066, 2017 | | 2017 |
A Novel Immunotherapy Increases Trafficking of Human Cytotoxic T-Cells to Colorectal Cancer Using a Targeted Bispecific Antibody L Kone, G Qiao, A Thakur, G Brown, S Khetani, B Prabhakar, LG Lum, ... ANNALS OF SURGICAL ONCOLOGY 27 (SUPPL 1), S18-S18, 2020 | | 2020 |
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma … MH Abidi, R Agarwal, N Tageja, L Ayash, A Deol, Z Al-Kadhimi, J Abrams, ... Biology of Blood and Marrow Transplantation 19 (1), 56-61, 2013 | 26 | 2013 |
A Phase I study of bortezomib during maintenance phase after high-dose melphalan and autologous stem cell transplantation in patients with multiple myeloma MH Abidi, Z Gul, LG Lum, J Abrams, S Cronin, M Ventimiglia, A Deol, ... Blood 116 (21), 2387, 2010 | 1 | 2010 |
A phase I study targeting newly diagnosed glioblastoma with anti-CD3× anti-EGFR bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide C Fadul, J Kim, A Thakur, J Kassay-McAllister, D Schalk, B Purow, ... Brain Tumor Research and Treatment 10 (Suppl), 2022 | 2* | 2022 |
A phase Ia/Ib trial of chemotherapy followed by infusions of activated T cells armed with OKT3 x trastuzumab bispecific antibody, IL-2 and GM-CSF for stage II/ III, Her2+ or … DB Jagtap, R Rathore, A Thakur, G Colvin, N Kouttab, A Maizel, A Deol, ... Cancer Research 74 (19_Supplement), 2806-2806, 2014 | | 2014 |